Monika Engelhardt

Severe cold hemagglutinin disease (CHD) successfully treated with rituximab.

Myelodysplastic syndrome in transformation to acute myeloid leukemia presenting with diabetes insipidus: due to pituitary infiltration association with abnormalities of chromosomes 3 and 7.

Telomere maintenance in human B lymphocytes.

CD34- hematopoietic stem cells: current concepts and controversies.

Side-population cells from different precursor compartments.

Striking complete remission after interferon-alpha for secondary recurrent non-Hodgkin's lymphoma but rare interferon-induced side effects.

Telomeres and telomerase in normal and leukemic hematopoietic cells.

Nonclonal neutrophil responses after successful treatment of myelodysplasia with low-dose 5-aza-2'-deoxycytidine (decitabine).

Epidemiology of non-Hodgkin's lymphoma (NHL): trends, geographic distribution, and etiology.

Telomere length and hTERT expression in patients with acute myeloid leukemia correlate with karyotypic instability.

Successful treatment of a patient with myelodysplastic syndrome (RAEB) with Darbepoetin-alfa in combination with Pegfilgrastim.

Occurrence of multiple myeloma 13 years after Hodgkin's disease: chance or consequence?

Incidence of monoclonal B-cell disease in siblings of patients with multiple myeloma.

Whole-body MRI in the detection of bone marrow infiltration in patients with plasma cell neoplasms in comparison to the radiological skeletal survey.

Intensive chemotherapy with autologous peripheral blood stem cell transplantation during a 10-year period in 64 patients with germ cell tumor.

State of the art therapy in multiple myeloma and future perspectives.

160 years of multiple myeloma: progress and challenges.

Primary (AL) amyloidosis in plasma cell disorders.

Bortezomib in combination with intermediate-dose dexamethasone and continuous low-dose oral cyclophosphamide for relapsed multiple myeloma.

Essential role of stromally induced hedgehog signaling in B-cell malignancies.

Characterization of in vitro growth of multiple myeloma cells.

Frequency, severity and risk factors for oral mucositis after BEAM conditioning and autologous peripheral blood stem cell transplantation: a single center analysis and review of the literature.

Chemotherapy safety and severe adverse events in cancer patients: strategies to efficiently avoid chemotherapy errors in in- and outpatient treatment.

Detection of renal impairment as one specific comorbidity factor in multiple myeloma: multicenter study in 198 consecutive patients.

Superiority of magnetic resonance imaging over conventional radiographs in multiple myeloma.

Consensus statement from European experts on the diagnosis, management, and treatment of multiple myeloma: from standard therapy to novel approaches.

Therapeutic drug monitoring of posaconazole in hematology patients: experience with a new high-performance liquid chromatography-based method.

Monitoring bortezomib therapy in multiple myeloma: screening of cyclin D1, D2, and D3 via reliable real-time polymerase chain reaction and association with clinico-pathological features and outcome.

Nephrotoxic chemotherapy.

European Myeloma Network: the 3rd Trialist Forum Consensus Statement from the European experts meeting on multiple myeloma.

Correspondence (letter to the editor): Ordering errors were identified.

Association of multiple myeloma with different neoplasms: systematic analysis in consecutive patients with myeloma.

Stevens-Johnson/toxic epidermal necrolysis overlap syndrome following lenalidomide treatment for multiple myeloma relapse after allogeneic transplantation.

Management of multiple myeloma in pregnancy: strategies for a rare challenge.

Early and mature endothelial progenitors and VEGFR2+-cells in multiple myeloma: association with disease characteristics and variation in different cell compartments.

Prognostic risk factor evaluation in patients with relapsed or refractory multiple myeloma receiving lenalidomide treatment: analysis of renal function by eGFR and of additional comorbidities by comorbidity appraisal.

Marrow versus blood-derived stem cell grafts for allogeneic transplantation from unrelated donors in patients with active myeloid leukemia or myelodysplasia.

Challenging the current approaches to multiple myeloma- and other cancer-related bone diseases: from bisphosphonates to targeted therapy.

Does colorectal cancer in ulcerative colitis patients constitute a risk for chemotherapy refractoriness?:a systemic approach by detailed analysis via the electronic tumor base documentation system.

Monitoring APC/C activity in the presence of chromosomal misalignment in unperturbed cell populations.

Aggressive plasmablastic lymphoproliferation complicated by hemophagocytic syndrome 12 years after heart transplant.

Similar incidences of TP53 deletions in extramedullary organ infiltrations, soft tissue and osteolyses of patients with multiple myeloma.

Use of systemic antifungals in daily clinical practice in the haematology and oncology setting: results of a prospective observational analysis.

Treatment option of bendamustine in combination with rituximab in elderly and frail patients with aggressive B-non-Hodgkin lymphoma: rational, efficacy, and tolerance.

Cell cycle control in acute myeloid leukemia.